<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONC-17012896</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-10-07</date_registration>
      <primary_sponsor>Xiangya Hosptial of Central South University</primary_sponsor>
      <public_title>Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide Combined with Short-Term Methotrexate for Severe Aplastic Anemia</public_title>
      <acronym>PTCy with MTX post HIT at SAA</acronym>
      <scientific_title>Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide Combined with Short-Term Methotrexate for Severe Aplastic Anemiaï¼ša multicenter, prospective, open-label, single-arm II/III phase study</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-10-01</date_enrolment>
      <type_enrolment />
      <target_size>Case series:30;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=22056</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Aplastic Anemia</hc_freetext>
      <i_freetext>Case series:Post-Transplant Cyclophosphamide Combined with Short-Term Methotrexate;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Bin Fu</firstname>
        <middlename />
        <lastname />
        <address>87 Xiangya Road, Changsha, Hu'nan, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 0731 89753731</telephone>
        <email>xyfubin@126.com</email>
        <affiliation>Xiangya Hosptial of Central South University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Bin Fu</firstname>
        <middlename />
        <lastname />
        <address>87 Xiangya Road, Changsha, Hu'nan, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 0731 89753731</telephone>
        <email>xyfubin@126.com</email>
        <affiliation>Xiangya Hosptial of Central South University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. aged 2 to 65 years (including 2 and 65 years);
2. severe aplastic anemia or transplansion dependant aplastic anemia by Camitta criteria;
3. No HLA matched sibling or unrelated donor,or requiring prompt transplantation without finding HLA consistent donor opportunities;
4. sign informed consent.</inclusion_criteria>
      <agemin>2</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. The physical fitness score is less than 70 points;
2. HCT specificity prognostic index (HCT-CT) was greater than 4 (including 4 points);
3. uncontrolled viral, bacterial, and fungal infections (progression of disease during antifungal therapy);
4. HIV seropositive;
5. malignant tumor;
6. pregnant and lactating women;
7. men and women who do not agree to contraception during the trial period;
8. researchers believe that patients are not eligible for clinical trials.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>over survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Rate of aGVHD;Incidence of regimen-related mortality;incidence of chronic GVHD;Sustained engraftment;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Researchers</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-09-12</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>